Treatment

Only one treatment is presently recommended for ischemic stroke: thrombolysis, which aims at dissolving the blood clot. This emergency treatment is being administered to approximately 15% of patients overall, mainly because it must be done within 4h and 30 minutes of the onset of stroke symptoms, in a specialized neurovascular hospital unit.

Moreover, because this treatment induces bleedings in some patients, it is subjected to some contraindications. Finally, its efficacy remains limited to an estimated 40% success rate. As a result, it is estimated that only 5% of ischemic stroke victims are successfully treated with thrombolysis.

So while this treatment is very useful for ischemic stroke, a major need for a new stroke treatment capable of effectively treating a majority of ischemic stroke patients remains.

Antiplatelet drugs (which inhibit blood platelets aggregation) proved their efficacy in ischemic diseases like myocardial infarction, but they are not recommended for stroke because they tend to induce bleedings that have catastrophic consequences in the brain.

Because of this context, Acticor Biotech took on the mission to develop an innovative antiplatelet compound that will suit the needs of clinicians: an effective action against the formation and growth of the blood clot responsible for the ischemia, without increasing bleeding risks.